Stockreport

Why Sangamo Therapeutics (SGMO) Is Down 21.1% After Steep Q3 Revenue Drop and Nasdaq Compliance Extension [Yahoo! Finance]

Sangamo Therapeutics, Inc.  (SGMO) 
Last sangamo therapeutics, inc. earnings: 2/28 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.sangamo.com
PDF net loss of US$34.93 million, while also disclosing new advancements in its clinical pipeline and ongoing efforts to secure business partnerships and regulatory clarity [Read more]